Astec LifeSciences Limited has informed the Exchange regarding Outcome of Board Meeting held on June 24, 2025.
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.5 pts more than Nifty Microcap 250 and 7.6 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Astec LifeSciences, at its meeting on June 24, 2025, approved a Rights Issue of fully paid-up equity shares with a face value of Rs. 10 each, for an amount not exceeding Rs. 250 Crore. The issue will be offered to eligible equity shareholders as on a record date, which will be notified later. Key details such as the issue price, rights entitlement ratio, record date, timing, and payment terms are yet to be finalised by the Board or a duly constituted committee. The issue is subject to applicable regulatory and statutory approvals under the Companies Act, 2013 and SEBI ICDR Regulations. The company has not disclosed the intended use of proceeds in this filing.
Eligible shareholders will get the opportunity (and the need) to subscribe to maintain their stake, as unexercised rights will lead to dilution. The Rs. 250 Crore capital infusion could strengthen the company's balance sheet, though the lack of disclosed purpose leaves the strategic intent unclear for now.